Imcyse is a developer of active specific immunotherapies for the treatment and prevention of severe chronic diseases caused by disruptions of the immune system. Its active immunotherapy technology platform allows it to destroy locally the immune cells involved in the destruction of the diseased organ.
|Employees (est.) (Nov 2019)||31|
Imcyse total Funding
Imcyse latest funding size
Time since last funding
|5 months ago|
|LSP BioVentures, SFPI-FPIM, Belfius Bank, W.IN.G, Philippe Degive|
When was Imcyse founded?
Imcyse was founded in 2010.
Who are Imcyse key executives?
Imcyse's key executives are Pierre Vandepapeliere, Thomas Taapken and Marcelle van Mechelen.
How many employees does Imcyse have?
Imcyse has 31 employees.
Who are Imcyse competitors?
Competitors of Imcyse include Atara Biotherapeutics, NeuralStem and Keros Therapeutics.
Receive alerts for 300+ data fields across thousands of companies